DiaMedica enrolls 200th patient in ReMEDy2 acute ischemic stroke trial

DiaMedica Therapeutics announced it enrolled the 200th patient in its ReMEDy2 Phase 2/3 acute ischemic stroke trial, with interim analysis results expected in Q1 2027.

Detected & updated continuously · Source: Nebula